BRAF and neoplasm: Based on the finding that cell survival in these tumours actually depends on this pathway [27, 28], ground-breaking progress has been made in the treatment of BRAF-mutated advanced melanoma over the last years owing to the development of specific inhibitors targeting BRAFV600E/K or MEK [4, 5, 10, 11].